Morgan Stanley Sees Positive Outlook Ahead for Boston Scientific

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $15.00 price target on

. In the report, Morgan Stanley noted, “Our analysis suggests margin expansion in 2014 is the beginning of an underappreciated leverage inflection. As sales investment drive returns over the next 12-18-months we see upside to top and bottom line performance and peer leading EPS growth. Reiterate OW.” Boston Scientific Corporation closed on Tuesday at $12.85.